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INTRODUCTION 
Tablets have always been the most preferred formulation for drug 
administration via oral route. Tablets constitute around 70-80% of the total 
formulations available in the market. However, there are limitations which make tablets 
as a secondary option when formulating new drugs. This is attributed to the physico-
chemical properties as well as pharmacokinetic parameters of the drug intended for 
formulation such as aqueous solubility, bioavailability, absorption rate and half-life etc. 
Such limitations can be overcome by opting alternate routes of drug administration. 
One such route is buccal drug delivery. 
Buccal Drug Delivery [1] 
Buccal drug delivery is a newly adapted route of 
drug administration through the mucous 
membrane, lining the cheeks internally. Buccal 
drug delivery often involves a formulation which 
contains bio-adhesive or mucoadhesive material, 
which adheres to the buccal mucosa over a period 
of time and releases the drug. Both local and 
systemic drug action is possible by buccal route. 
There are two permeation pathways by which the 
drug gets transferred from the site of adhesion to systemic circulation. They are 
paracellular (between the cells) and transcellular (across the cells) pathways. The 
permeating drug can adapt both the pathways simultaneously, but often through one 
pathway preferably than the other, depending on the physico-chemical properties of 
the drug. The permeated drug gets absorbed into the reticulated vein which lies 
underneath the oral mucosa and transported through the facial veins, internal jugular 
vein, brachiocephalic vein and then drained into the systemic circulation. 
 
Fig-1: Oral cavity and 
location of buccal mucosa 
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A. Structure of buccal mucosa 
Buccal mucosa is composed of an outermost layer of stratified 
squamous epithelium (Figure 2). Below this, lies a basement membrane, a lamina 
propria followed by the submucosa as the innermost layer. The epithelium is similar to 
stratified squamous epithelia found in the rest of the body in that it has a mitotically 
active basal cell layer, advancing through a number of differentiating intermediate 
layers to the superficial layers, where cells are shed from the surface of the epithelium. 
The epithelium of the buccal mucosa is about 40-50 cell layers thick, while that of the 
sublingual epithelium contains somewhat fewer. The epithelial cells increase in size 
and become flatter as they travel from the basal layers to the superficial layers. 
 
 
 
 
 
 
 
Fig-2: Histology of buccal mucosa 
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B. Factors affecting absorption of drugs through buccal mucosa 
The major factors which affect the absorption of drug through buccal 
mucosa can be grouped as, 
i) Physiological factors - permeability of buccal mucosa 
ii) Physico-chemical factors – properties of the drug 
 
i) Permeability of buccal mucosa [1] 
The buccal mucosae in general is relatively a leaky epithelial 
intermediate between that of the epidermis and intestinal mucosa. It is estimated that 
the permeability of the buccal mucosa is 4-4000 times greater than that of the skin. As 
indicative by the wide range in this reported value, there are considerable differences 
in permeability between different regions of the oral cavity because of the diverse 
structures and functions of the different oral mucosae. In general, the permeabilities of 
the oral mucosae decrease in the order of sublingual greater than buccal, and buccal 
greater than palatal. This rank order is based on the relative thickness and degree of 
keratinization of these tissues, with the sublingual mucosa being relatively thin and 
non-keratinized, the buccal mucosa is thicker and non-keratinized, and the palatal is 
intermediate in thickness but keratinized. 
 
ii) Physicochemical properties of the drug [2] 
The physicochemical properties which influence the drug absorption 
through buccal mucosa are described as follows: 
a. Molecular weight 
Molecules of smaller size penetrate the buccal mucosa better than 
macromolecules (e.g: peptides) and ions. 
b. Degree of ionization 
Unionized form of drugs can cross the lipoidal membranes easily 
compared to their ionized counterparts. Both pKa of the drug and pH of the buccal 
environment, which averages from 6.6-6.8, can influence the absorption through buccal 
mucosa. 
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c. Partition coefficient 
More lipid soluble the compound, higher will be its penetration through 
the buccal membrane. Hence, compounds of high oil-water partition coefficient (40-
200) can permeate well through buccal mucosa. 
 
C. Mechanism of bioadhesion [3] 
Bioadhesion may be defined as the state in which two materials, among 
which, one is of a biological nature, are held together for extend periods of time by 
interfacial forces. Several theories have been proposed to explain bioadhesion. Any 
mechanism of adhesion requires the establishment of molecular contact between the 
bioadhesive material and mucin/epithelial cell surface. In a particular system more than 
one mechanism may contribute to the formation of bioadhesive bonds which can be 
specific or non-specific, and can involve covalent or non-covalent bonds. The proposed 
theories of bioadhesion include, 
i. Electronic theory 
A double layer of electrical charge is formed at the interface between an 
adhesive polymer and mucus, due to different electronic characteristics, giving rise to 
an attractive force from electron transfer across the electrical bilayer.  
ii. Adsorption theory 
A bioadhesive polymer adheres to mucus, because of a secondary 
surface force, such as Van der Waal’s force, hydrogen bonds or hydrophobic 
interaction. 
iii. Wetting theory 
This theory is primarily applicable to liquid bioadhesive systems. 
Bioadhesion over a wet surface is determined by structural similarity, degree of cross-
linking and use of a surfactant. 
 
iv. Diffusion theory 
Diffusion theory proposes that polymeric chains of the adhesive and the 
substrate interacts with each other to a sufficient depth, to create temporary adhesive 
bond.  
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The rate of penetration depends upon the diffusion coefficient of the 
polymer, which in turn is influenced by the molecular weight and cross linking density.  
 
D. Advantages of Buccal drug delivery [4,5] 
 Avoiding first pass effect: 
Certain drugs undergo extensive first pass metabolism and hence their 
absolute bioavailability is very less (1-10%). In order to overcome this, drugs are 
incorporated into a buccal drug delivery system, which exploit the high vasculature of 
buccal mucosa. Direct access to the systemic circulation through the internal jugular 
vein avoids acid hydrolysis in the gastrointestinal (GI) tract. Thus this provides an 
alternative for administration of hormones, narcotic analgesics, steroids, enzymes, 
cardiovascular agents etc. 
 Improved patient compliance in pediatric and geriatric patients: 
Children often refuse to ingest tablets or sometimes syrups due to their 
organoleptic properties. In such cases, buccal drug delivery system may serve as an 
alternate formulation which may mimic a confectionery. Whereas in elderly people, 
due to the necessity of taking too many medications (for diabetes, hypertension and 
hyperlipidemia), they would rather prefer one lesser tablet than usual, whereby a buccal 
drug delivery system can come in handy. 
Termination of the therapy is easy. It can also be administered to 
unconscious patients. 
 Better absorption 
The process of absorption via buccal route is passive and rapid. 
Therefore, it does not require any activation. Among trans-mucosal drug delivery, 
buccal route lies second to sublingual delivery, while vaginal, rectal, transdermal routes 
exhibit poor absorption than buccal mucosa. 
 Easy to formulate: 
The number of intermediate steps involved in formulating a buccal drug 
delivery system is comparatively very less than a tablet manufacturing process. 
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E. Disadvantages of Buccal drug delivery 
 Drug related issues 
Drugs, which irritate the oral mucosa and have a bitter or unpleasant 
taste and odour, cannot be administered by this route. Drugs, which are unstable at 
buccal pH cannot be administered by this route. 
 Low permeability and surface area: 
Buccal mucosa exhibits comparatively low permeability than the 
sublingual region. The total surface area of the membranes of the oral cavity available 
for drug absorption is 170 cm2, of which approximately 50 cm2 represents non-
keratinized tissues, including the buccal membrane 
 Salivation: 
Salivation can dilute the drug and can make it pass through the pharynx 
to stomach. Some people possess the nature of excessive salivation wherein the dosage 
form find difficulties in adhering to the buccal wall. 
 Accidental chewing or swallowing: 
Children or even adults may accidentally chew off the formulation and 
the whole purpose of drug delivery through buccal mucosa becomes obsolete. A hazard 
of choking due swallowing of the patch is also possible. 
 
F. Formulation of buccal drug delivery systems [4]: 
The various types of buccal drug delivery systems include buccal 
tablets, films, patches, gels, ointments and powders. The difference between the term 
“patch” and “film” may be attributed to their thickness, where the former is thicker 
than the latter. Buccal patches can be formulated by adopting any of the following 
methods. 
i) Solvent casting method 
ii) Direct compression method 
iii) Hot-melt extrusion method 
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i) Solvent casting: 
In solvent casting method all the excipients are dispersed in suitable 
solvents and are mixed together. The mixture is added with required quantity of active 
pharmaceutical ingredient and allowed to settle till the solution is cleared of entrapped 
air. Then the solution is poured onto a mold or casting and allowed to dry. Patches of 
required size and geometry were cut from the parent patch. 
 
ii) Direct compression/milling method: 
The drug and the excipients are mixed together as a single physical 
mixture and kneaded with the help of a minimum quantity solvent. The wet mixture is 
rolled on the release linear till it achieves desired thickness and allowed to dry. 
 
iii) Hot-melt extrusion method(HME) [5]: 
 The required polymers are melted during the extrusion process, which 
can function as thermal binders and act as drug depots upon cooling and solidification. 
Since solvents and water are not necessary, the number of processing and drying steps 
are reduced. The intense mixing and agitation imposed by the rotating screw cause de-
aggregation of suspended particles in the molten polymer resulting in a more uniform 
dispersion and the process is continuous and efficient. Bioavailability of the drug 
substance may be improved when it is solubilized or dispersed at the molecular level 
in HME dosage forms. Pharmaceutical Hot-Melt Extrusion processes can be 
categorized as either ram extrusion or screw extrusion. 
Though there are no significant differences in the performance of the 
patches prepared by the above methods, solvent casting method is least preferred due 
to the possibility of residual solvent in the formulation and the corresponding solvent 
related health issues. 
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G. Composition of buccal patches [6] 
a) Active pharmaceutical ingredient: 
The selection of drug is a vital process when formulating a buccal patch. 
Potent drugs, i.e., drugs with a conventional dose of lesser than 100mg and drugs which 
undergo extensive first pass metabolism (which also exhibit low bioavailability, less 
than 20%) are preferred candidates for buccal drug delivery. Buccal patches are 
generally intended for sustained release, hence drugs with a half-life of 2-8 hours will 
be an apt candidate. pH is another factor to be considered when choosing a drug, since 
the drug or even any excipient should not irritate the buccal mucosa, due to acidity or 
alkalinity.  
b) Polymers: 
To serve as mucoadhesive polymers, the polymers should possess some 
general physiochemical features such as,  
 Predominantly anionic hydrophilicity with numerous hydrogen bond-forming 
groups. 
 Polymer and its degradation products should be non-toxic, non-irritant and free 
from leachable impurities. 
 Should have good spreadability, wetting, swelling and solubility and 
biodegradability properties. 
 pH should be biocompatible and should possess good viscoelastic properties. 
 Should possess peel, tensile and shear strengths at the bioadhesive range. 
 Should possess bioadhesive, film-forming and if required, sustained release 
properties.  
Such polymers include Hydroxy propyl cellulose(HPMC), Hydroxy 
ethyl cellulose(HEC), Polyvinyl alcohol(PVA), Carbopol, Polyvinylpyrrolidone 
(PVP) etc. 
c) Diluents: 
 If the drug is potent (dose less than 10mg), a suitable diluent such as 
Lactose may be added to increase the bulk of the formulation. Diluent such as 
microcrystalline cellulose is used when buccal tablets or patches are formulated by 
direct compression method. 
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d) Sweetening agent: 
Sucralose, Aspartame, Mannitol etc., can be used as sweetening agents. 
e) Flavouring agent: 
Vanillin, Clove oil, Menthol etc., may serve as suitable flavouring 
agents. 
f) Plasticizer: 
Plasticizer is a vital ingredient which determine most of the physical 
properties of the buccal patch such as elasticity, folding endurance, tensile strength etc. 
Hence reliable plasticizers such as Polyethylene glycol 100, 400, Propylene glycol and 
Dibutyl phthalate can be used. 
g) Permeation enhancer: 
Examples of permeation enhancers include Dimethyl sulphoxide 
(DMSO), Sodium taurocholate, Sodium glycocholate, Oleic acid, Cyanoacrylate etc. 
 
H. Evaluation of buccal patches [7] 
     Buccal patches are mainly evaluated for their physical properties, 
bioadhesion and release properties. The following are the important evaluation 
parameters with regard to buccal patches: 
a) Thickness: 
Thickness determines the uniformity of content in the patch and also its 
aesthetic value to an extent. Thickness can be measured using a digital screw gauge or 
calibrated digital micrometer. 
 
b) Weight variation: 
Weight variation is also determined to ensure content uniformity, since 
deviation in uniform weight is due to difference in the amount of either drug or the 
polymer matrix in an individual patch. 
 
c) Folding endurance: 
Folding endurance is determined by repeated folding of the patch at the 
same place till it breaks. The number of times the patch is folded without breaking is 
recorded as the folding endurance value. The concentration of plasticizer is responsible 
for the folding endurance of a patch 
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d) Tensile strength: 
Tensile strength is the maximum stress applied to a point at which the 
buccal patch breaks. Tensile strength can be calculated by the equation. 
 
 Tensile strength(kg/mm2) = F୭୰ୡୣ ୟ୲ ୠ୰ୣୟ୩I୬୧୲୧ୟ୪ ୡ୰୭ୱୱ−ୱୣୡ୲୧୭୬ୟ୪ ୟ୰ୣୟ  
 
e) Drug content: 
Determination of drug content in buccal patches can be carried out by, 
suitably dissolving the patches and diluting, to a get a clear solution, which can be 
estimated by any of the analytical methods such as UV spectrophotometry, fluorimetry, 
HPTLC or HPLC as suggested in the monograph of the drug incorporated. A sample 
of 3 patches may be subjected to the assay procedure to ensure the content uniformity. 
 
f) Swelling index: 
Swelling index is determined using simulated saliva solution (pH 6.8 
buffer solution). Each patch is weighed and placed in a pre-weighed stainless steel wire 
mesh. The mesh containing the patch is submerged into 4ml medium. Increase in the 
weight of the film was determined at pre-set time intervals until a constant weight is 
seen. The degree of swelling can be calculated using the following equation: 
 
Swelling index = Wୣ୧୥୦୲ ୟ୤୲ୣ୰ ୱwୣ୪୪୧୬୥ −I୬୧୲୧ୟ୪ wୣ୧୥୦୲ I୬୧୲୧ୟ୪ wୣ୧୥୦୲  
 
g) Surface pH: 
Determination of surface pH of a buccal patch formulation ascertains 
that the patch does not cause any local irritancy to the buccal mucosa. A number of 
methods can be employed to determine surface pH such as use of pH paper or digital 
pH meter, over the surface of the formulation, previously wetted with water. 
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h) In-vitro bioadhesion [8]: 
Several techniques such as tensile strength testing, adhesion weight 
method, fluorescent probe method, flow channel technique, colloidal gold staining 
method are employed to determine bioadhesive strength of buccal patches. 
A fabricated setup which consist of a modified physical balance is used 
to determine the bioadhesive strength of the buccal patches. 
  
i) In-vitro diffusion/permeation [9]: 
A Franz diffusion cell can be used to study the drug diffusion or 
permeation pattern. Cellulose nitrate filter can be used as an artificial membrane to 
mimic the buccal mucosa [10]. The diffusion medium used is phosphate buffer solution 
(PBS) at a pH of 6.8, which acts as simulated saliva. 
 
j) In-vivo bioavailability [11]: 
In-vivo bioavailability studies are preferably carried out with the help 
of human volunteers. Proper permission must be sought from the ethical authorities, 
prior to the study. An informed consent must be given to the volunteers and the 
Declaration of Helsinki guidelines must be followed throughout the course of the study. 
 The buccal patches must be administered to the volunteers and blood 
samples are collected periodically. The samples are subjected to suitable extraction 
methods and analyzed for the concentration. The pharmacokinetic parameters such as 
Cmax, tmax, Kel, t1/2, AUC, AUMC and MRT are determined using the plasma 
concentration-time data and thus bioavailability is calculated. 
The other methods specific for monitoring bioadhesion include Gamma 
scintigraphy, isolated loop technique and transit studies with radiolabelled or 
fluorescent coupled dosage forms. 
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REVIEW OF LITERATURE 
Choy Fun Wong et al., (1999) [12], fabricated controlled release buccal 
patches containing Metoprolol tartrate, using Eudragit-NE40D, along with other 
polymers such as HPMC, Sodium CMC and Carbopol of different grades to modify the 
mucoadhesive property. Although high viscosity polymers can enhance the bio-
adhesiveness of the patches, they also tend to cause non-homogeneous distribution of 
the polymers and drug, resulting in non-predictable drug-release rates. Of the various 
bioadhesive polymers studied, Cekol-700 appeared to be most satisfactory in terms of 
modifying the drug release and enhancement of the bioadhesive properties. 
Addolorato. G et al, (2003) [13], have reviewed about the use of 
Metadoxine in the treatment of acute and chronic alcoholism. In this review, the 
preclinical and clinical results obtained using Metadoxine in acute and chronic alcohol 
intoxication were reported. Metadoxine also seems to be safe; in more than 15 years of 
post-marketing surveillance. Only minor aspecific and reversible events were observed 
in patients exposed to the treatment. 
Neeraj Kaul et al., (2005) [14], have developed a stability indicating 
method for determination of Metadoxine in pharmaceutical dosage forms, using 
HPTLC. The method involved use of TLC Aluminium plates pre-coated with silica gel 
60F-254 as the stationary phase. The solvent system consisted of acetone–chloroform–
methanol–ammonia (7.0: 4.0: 3.0: 1.2, v/v/v/v). Densitometric analysis of Metadoxine 
was carried out in the absorbance mode at 315 nm. Metadoxine was subjected to acid, 
alkali and neutral hydrolysis, oxidation, dry and wet heat treatment and photo and UV 
degradation. The drug undergoes degradation under all stress conditions. Also, the 
degraded products were well resolved from the pure drug with significantly different 
Rf values. 
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Pradeep kumar et al., (2008) [15], have developed and validated a 
spectrophotometric method to estimate Metadoxine in bulk and pharmaceutical dosage 
forms using derivative spectroscopy. The method was based on Metadoxine, showing 
absorbance at 292, 302, 270 and 314 nm for zero order, first order, second order and 
third order derivative spectroscopy respectively in distilled water. But regression values 
with best results were found to be best for third order derivative spectroscopy. The 
method obeyed Beer’s law in the concentration range of 4 to 40μg/ml. The proposed 
method was precise, accurate, linear, stable and reproducible and can be extended to 
the analysis of Metadoxine in bulk and tablet formulations. 
Surya N. Ratha et al., (2010) [8], have attempted to formulate a buccal 
drug delivery system containing Atenolol using Sodium alginate along with various 
hydrophilic and mucoadhesive polymers like CP 934 P, Sodium CMC, and HPMC in 
various proportions and combinations. Buccal patches of Atenolol provided sustained 
buccal delivery of atenolol for a long period and promised to be a good way to bypass 
the extensive hepatic first-pass metabolism in the management of hypertension. 
P. Chinna Reddy et al., (2011) [5], have reviewed on bioadhesive buccal 
drug delivery systems and their current status of formulation and evaluation methods. 
This article describes about the nature of buccal mucosa and pathways of drug 
absorption through it; it’s advantages, limitations and scope for improvisation. They 
have also elaborated on the various types of buccal drug delivery systems, formulation 
techniques, composition of buccal drug delivery systems and their evaluation 
techniques. 
Ikoni J. Ogaji et al., (2011) [16], have reviewed the current applications 
of natural polymeric materials in pharmaceutical formulations. The pharmaceutical 
applications of some of the traditional and commercially available natural polymers 
were discussed. Emerging potential pharmaceutical excipients of natural origins such 
as Xyloglucan, Pullulan, Pectin, starches, Moringa oleifera gum etc., were also 
discussed. 
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Ravi Kumar et al., (2012) [17], have isolated and characterized mucilage 
obtained from unripened fruits (endosperms) of Borassus flabellifer. This study 
elucidated the physical, thermal, sorption and functional properties of Borassus 
flabellifer mucilage, by elemental analysis, Fourier transmittance infra-red analysis, 
particle size analysis, thermogravimetric analysis, differential scanning calorimetry, 
scanning electron microscopy and X-ray powder diffraction. 
In a different study, Ravi Kumar et al., (2012) [18], have also studied 
the use of mucilage obtained from fruits of Borassus flabellifer as a natural gelling 
agent. Mucilage extracted from endosperm of Borassus flabellifer fruit was subjected 
to toxicity studies for its safety and preformulation studies for its suitability as a gelling 
agent. Diclofenac sodium was used as model drug for the formulation of gels. Thus it 
was concluded that the Borassus flabellifer mucilage can be used as a pharmaceutical 
excipient in gel formulations and it has the potential to replace some synthetic gelling 
polymers upon further modifications. 
Waleed Khattab et al., (2013) [19], have formulated buccal tablets 
containing Zolmitriptan using different mucoadhesive polymers (natural and synthetic) 
in different ratios by direct compression technique. All tablets showed acceptable 
mucoadhesive strength. In-vitro drug release studies showed that at least 76 % of the 
drug was released within 7 hrs. Release of Zolmitriptan from all tablets followed zero 
order kinetics. Hence, these formulations of are promising ones as a controlled drug 
delivery system that will lead to improved bioavailability and greater therapeutic 
efficacy. 
Amelia M. Avachat et al., (2013) [20], developed mucoadhesive buccal 
films using tamarind seed xyloglucan (TSX) as novel mucoadhesive polysaccharide 
polymer for systemic delivery of Rizatriptan benzoate through buccal route. Ex vivo 
diffusion studies were carried out using Franz diffusion cell, while bioadhesive 
properties were evaluated using texture analyzer with porcine buccal mucosa as model 
tissue. This study suggests that tamarind seed polysaccharide can act as a potential 
mucoadhesive polymer for buccal delivery of a highly soluble drug like Rizatriptan 
benzoate. 
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Khadir. A et al., (2013) [10], have investigated the use of model 
polymeric membranes; cellulose acetate and cellulose acetate-nitrate, as an alternative 
to the natural mucosa. Permeability coefficient and steady-state flux for Carvedilol 
were determined in natural and artificial membranes. The effect of chemical enhancers 
on permeability through polymeric membranes was measured and compared against 
that in porcine and rabbit mucosa. A strong and statistically significant correlation 
between artificial membranes and buccal mucosa for the delivery of carvedilol was 
established. 
Ann Rose Augusthy et al., (2014) [21], have attempted to formulate 
buccal patches containing Rabeprazole sodium using HPMC, PVP and Gelatin. The 
patches were prepared and evaluated for their thickness uniformity, folding endurance, 
weight uniformity, content uniformity, and in-vitro release studies were conducted for 
Rabeprazole loaded patches in phosphate buffer (pH-6.8) solution. 
Jeevan Sen et al., (2014) [22], have studied the in-situ gel forming 
properties of Chitosan and Gellan gum, in the administration of Clotrimazole as a 
vaginal mucoadhesive drug delivery. Conventional topical application of Clotrimazole 
to skin may cause localized irritation of the skin with a mild burning sensation, redness 
and itching. The formulations were characterized for various in-vitro parameters e.g. 
clarity, pH, isotonicity, viscosity, drug release profile, statistical release kinetics, 
bioadhesive force, retention time, microbial efficacy, irritation test and stability studies. 
The developed formulation was found to be non-irritant, bioadhesive with good 
retention properties. Hence the developed formulation was suggested as an alternative 
for vaginal dosage forms. 
Shivhare. U.D et al., (2014) [9], have formulated buccal patches loaded 
with Aceclofenac using HPMC-E15 and Eudragit RL-100, in an attempt to enhance the 
bioavailability of the drug, which is usually 40-50%, due to extensive first pass 
metabolism. This study was also focused reducing the dosing frequency of the drug by 
formulating it into a sustained-release form.  Among five formulations, patch prepared 
with 1:1 ratio of HPMC-E15 & Eudragit RL-100 showed maximum release 92.35% up 
to 8 hours. 
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Bhattacharjee. S et al., (2014) [23], have studied the effect of varying 
concentrations of plasticizer on the physical properties of mucoadhesive films. Buccal 
films were prepared by using Hydroxy Propyl Methyl Cellulose (HPMC) as the 
polymer and Glycerine, Propylene glycol, Dibutyl phthalate, Triethanolamine as 
plasticizers. Methanol and Acetone were used as solvents. It was concluded that buccal 
films prepared by using Propylene glycol as the plasticizer in the solvent Methanol, 
promotes sustained drug release over a period of 6 hours of study and hence proved to 
be a good plasticizer in formulating buccal films. 
Vengaiah. P.C et al., (2015) [24], have studied Borassus flabellifer fruit 
pulp for its physico-chemical properties. From this study, it was observed that the fresh 
pulp contains a moisture content of 74.5%. The ash and fat contents (wet matter basis) 
were 1.2% and 0.8% respectively. The protein content and carbohydrate content were 
1.25% and 22.5% respectively. The calorific value obtained was 102.83 kcal/100g. The 
pH value was 5.5. Water absorption capacity (18%) and bulk density (0.78 g/cm3) were 
recorded for the Palmyra fruit pulp. The values for swelling power and foam capacity 
were 4% and 2.5% respectively. 
Saranya. P and Poongodi Vijayakumar. T, (2016) [25], have carried 
out a phytochemical screening of raw and thermally processed Borassus flabellifer fruit 
pulp. The results revealed that both the raw and processed Palmyra palm fruit pulp 
contain all the phytochemicals such as carbohydrates, alkaloids, flavonoids, tannins, 
glycosides, saponins and phenolics, except proteins. On processing, alkaloids were 
reduced in the aqueous extract of processed pulp and saponins in both the extracts of 
raw and processed pulp. Therefore, no major changes in the presence of phytochemical 
components due to heat processing were found in this current study. 
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SCOPE OF THE WORK 
 Buccal drug delivery seems to be a boon for formulation researchers, 
especially when formulating a sustained release formulation or when facing a difficulty 
with a drug which undergoes first-pass effect. The polymers used are also of natural or 
semisynthetic origin, which gives a wider scope of using natural polymers. This work 
focuses on using a novel mucoadhesive polymer obtained from Palmyra palm. 
1. Palmyra palm fruit resin-a novel mucoadhesive polymer: 
A number of researchers have worked on using polymers of natural 
origin as excipients in novel drug delivery systems, since natural polymers offer the 
advantage of biocompatibility and abundance. One such polymer of plant origin which 
has been underutilized in spite of its numerous uses is resin obtained from the fruit pulp 
of Palmyra palm. 
Palmyra palm or Asian palm is a tall erect tree abundantly found in 
Asian countries from the Persian Gulf to the Cambodian-Vietnamese border and are 
specifically cultivated in India, Sri Lanka, Malaysia and in some American regions like 
Hawaii and Florida. 
 
Fig-3: Palmyra palm trees 
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Each palm may bear 6-12 bunches of about 50 fruits per year. An 
average crop of Palmyra palm in Sri Lanka is 350 fruits. In India, it is grown as a 
windbreak over the plains. The coconut-like fruits are three-sided when young, 12-15 
cm wide, and capped at the base with overlapping sepals. The outer covering is smooth, 
thin, leathery and brown, turning nearly black after harvest. Inside is a juicy mass of 
long, tough, coarse, white fibers coated with yellow or orange pulp. When the fruit is 
very young, this kernel is hollow, soft as jelly, and translucent like ice and is 
accompanied by a watery liquid, which is sweetish and potable. The pulp of mature 
fruits is sucked directly from the wiry fibers of roasted, peeled fruits. It is also extracted 
to prepare a product called punatoo in Sri Lanka. It is eaten alone or with the starch 
from the Palmyra seedlings. The fresh pulp is reported to be rich in vitamins A and C. 
The pulp of the mature fruit can be used in the treatment of dermatitis [26]. 
This processed fruit pulp is usually a sticky mass and remains in the 
mouth for a longer period. This formed the basis for using this resinous extract as 
mucoadhesive polymer. 
 
2. Alcoholism 
People of the modern world assume social drinking (alcohol 
consumption) as an indication of one’s social status or the ability to get along with the 
society or peer group. In the course of this action, they often tend to forget the serious 
adverse effects associated with alcohol consumption, especially the level of damage 
that one’s liver might be subjected to. Alcohol intoxication can be described as a 
change or a disturbance in the behaviour or mental function of an individual during or 
after consumption of alcohol.  
More excessive or serious forms of drinking, often chronic, may be 
potentially harmful to the drinker and to others affected by the drinker. For example, 
drinking with the intent to get drunk or intoxicated, drinking and driving while under 
the influence of alcohol, loss of psychomotor coordination and speech, blackouts, 
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vomiting and alcohol poisoning are considered among the harmful symptoms and 
effects of drinking that falls outside the scope of social drinking. In addition to the 
effects of alcohol on the nervous system, it may be one of the major contributing factors 
to road accidents, suicide and violent death in young adults. Alcohol intoxication can 
affect a person's judgement.  Sometimes, coma can occur. Alcohol intoxication is 
managed with rest, hydration and stopping alcohol use. Severe cases require hospital 
admission, intravenous fluids, observation and supportive care. Alcohol abuse, 
moreover, is a common problem in the general population all over the world. Alcohol 
abuse and alcoholism are responsible for a wide variety of medical problems, which 
are considered part of the new-age epidemics, among them the most recognized being 
alcohol-induced liver disease, primary and secondary malnutrition, and neuron 
damage, often leading to death. It would be desirable to avoid these and other effects 
or consequences of excessive alcohol consumption. 
In the Indian scenario, more than 10 million cases of alcohol intoxicated 
patients are reported per year (sources: Apollo Hospitals). As the debate over alcohol 
ban grows across India, 15 people die every day – or one every 96 minutes – from the 
effects of drinking alcohol, reveals an India Spend analysis of 2013 National Crime 
Records Bureau (NCRB) data, the latest available. The per capita consumption of 
alcohol in India increased 38%, from 1.6 litres in 2003-05 to 2.2 litres in 2010-12, 
according to a World Health Organization (WHO) report, which also revealed that 
more than 11% of Indians were binge drinkers, against the global average of 16 percent. 
Before the latest crackdowns on alcohol, Gujarat and Nagaland were the only Indian 
states with prohibition. Maharashtra tops alcohol-related deaths. Maharashtra reported 
the most alcohol-related deaths, followed by Madhya Pradesh and Tamil Nadu, 
according to the NCRB data, with experts saying high rates of alcoholism correlate 
with high crime rates [27]. 
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The most lasting damaging actions of ethanol are exerted on the liver 
function and structure. A liver disease is often present in patients affected by 
alcoholism; however, the mechanisms responsible for the liver toxicity of ethanol are 
still not completely understood. Ethanol also modifies the GABA-mediated 
neurotransmission. It preferentially stimulates the dopaminergic transmission in the 
mesolimbic system, interferes with serotoninergic transmission and with the release of 
glutamate in the central synapses. The neuropathological manifestations usually appear 
after many years of excessive drinking. The pharmaco-therapeutic aspect of alcoholism 
includes the use of drugs, with different actions and objectives. Among them, 
Metadoxine seems to be of interest [13]. 
Therefore, Metadoxine was chosen as a model drug for the development 
of buccal patches as an attempt to improve compliance in chronic alcohol addicts. 
3. What’s new? 
I. Usually films or patches, either transdermal or buccal involves a dose 
calculation based on the surface area. In this study, the ‘thickness’ factor is 
incorporated, enabling a more precise dose calculation, since the volume of the matrix 
is considered, i.e., a patch is considered as a three dimensional cylinder rather than a 
two dimensional circle. The dose calculation is proceeded as follows: 
Volume of a parent patch made up by a  
particular volume of polymer mixture/matrix = πR2h 
Volume of individual patch (final product) = πr2h 
where R  = radius of parent patch 
r = radius of individual patch 
      The number of possible patches (theoretically) = V୭୪୳୫ୣ ୭୤ ୮arୣ୬୲ ୮a୲ୡ୦V୭୪୳୫ୣ ୭୤ ୧୬ୢ୧୴୧ୢ୳a୪ ୮a୲ୡ୦ 
 Thus, the quantity of drug to be added  = Number of theoretical patches × 
Dose of individual patch 
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II.  A new laboratory scale hand punch for cutting the patches from a 
parent patch was fabricated, which helps in cutting the patches of fixed and uniform 
diameter. The base and the punches were fabricated with stainless steel. The punches 
with sharp edges, are screwed onto the base, so as to facilitate addition of new punches 
of variable diameter. 
 
  Handle 
     Base 
 
Punches 
 
 
 
Fig-4: Fabricated Patch Cutter 
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DRUG PROFILE 
METADOXINE [28] 
Synonyms : pyridoxine L-2-pyrrolidone-5-carboxylate 
IUPAC name : 4,5-bis(hydroxymethyl) - 2- methylpyridin – 3 -ol; 
   (2S) – 5 – oxopyrrolidone – 2 - carboxylic acid 
Empirical formula : C13H18N2O6 
Chemical structure : 
  
Molecular weight : 298.295 g/mol 
Appearance : white or almost white crystalline powder 
Solubility : freely soluble in water and methanol, soluble in Ethanol, 
insoluble in chloroform and Diethyl ether 
Melting point : 97°-100° C, meanwhile decomposition on melting is observed 
Optical rotation : -9.0° to -12.5° 
Category : Hepatoprotective 
Brand names : Metadoxil (Micro Labs Ltd.), Alcoliv (Sun Pharmaceutical 
Industries Ltd.), Viboliv (Dr. Reddy’s Laboratories Ltd.), 
Livodox (Icon Life Sciences Ltd.), Toneliv (Esmatrix Life 
Sciences Ltd.) 
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Mechanism of action [29]: 
 Metadoxine is a selective antagonist of the serotonin receptor subtype 
5-HT2B and displays high affinity to the gamma-aminobutyric acid (GABA) 
transporter. In vitro enzymatic assay revealed that Metadoxine reduced the activity of 
the GABA transaminase enzyme, responsible for the degradation of GABA. 
Electrophysiological studies also showed that Metadoxine increased inhibitory GABA 
based synaptic transmission via a presynaptic effect. As it does not affect dopamine, 
norepinephrine or serotonin levels, Metadoxine displays a novel mechanism of action 
as a monoamine-independent GABA modulator. 
 Its primary effect is to increase elimination of alcohol via the kidneys, 
and to help clear the by-products of alcohol decomposition, such as acetaldehyde, from 
the blood and tissues. The process of oxidizing ethanol into acetaldehyde and acetone 
consumes reduced glutathione levels. Following a consumption of alcohol, Metadoxine 
helps restore nicotinamide-adenine-dinucleotide (NAD), glutathione, and adenosine 
triphosphate (ATP) concentration in the liver and the brain, as well as normalizes 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-
glutamyl transpeptidase (GGT) levels, all of which are characteristic signs of liver 
regeneration. 
Pharmacokinetics [13]: 
 The oral absorption of the drug is fast, with high and reproductive absolute 
bioavailability (60 to 80%).  
 It undergoes extensive tissue distribution and hence large apparent distribution 
volume is observed.  
 The half-life is 40 to 60 minutes without appreciable differences between oral or 
intravenous administration. 
 Excretion occurs approximately in the same proportion through the urine and the 
feces, between 40 and 45% in 24 hours in the urine, and between 35 and 50% in 96 
hours in the feces. 
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Indications: 
 Treatment of alcohol intoxication; 500-1000mg orally twice daily 
 Treatment of fatty liver - both alcoholic and non-alcoholic 
 Treatment of ADHD 
 Treatment of Fragile X Syndrome  
Side effects [30]: 
 No unfavorable side effects are reported that could be attributed to 
the drug. Therefore, Metadoxine be considered a valuable resource in the treatment of 
alcoholic liver disease. 
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POLYMER PROFILES 
I. Borassus flabellifer Fruit Resin 
Synonyms : Asian palm, Palmyra palm, Toddy palm, Cambodian palm 
Source : Ripened fruit pulp of B. flabellifer 
Taxonomy [31,32] :  
Kingdom Plantae 
   Subkingdom Viridiplantae 
      Infrakingdom Streptophyta 
         Superdivision Embryophyta 
            Division Tracheophyta 
               Subdivision Spermatophytina 
                  Class Magnoliopsida 
                     Superorder Lilianae 
                        Order Arecales 
                           Family Arecaceae 
                              Genus Borassus L. 
                                 Species Borassus flabellifer L. 
Appearance : Golden brown or dark brown sticky resinous substance 
Odour :  Sweet and fruity smell 
Solubility : Soluble in water, sparingly soluble in Methanol, insoluble 
in Chloroform and Dichloromethane. 
Constituents [25] : Hemicellulose is the primary constituent of this resin, 
while it also contains traces of phyto-constituents like 
alkaloids, flavonoids, saponins, tannins & vitamins. 
pH  : 5.5 – 6 
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Swelling ratio [24]  : 4 g/g 
Moisture content : 74-77 % 
Water absorption capacity : 3 % 
Stability   
The resin is thermally unstable (above 60°C). But exhibits remarkable 
stability on storage at normal conditions (room temperature in an air-tight container). 
Even after 150 days since extraction, no fungal or bacterial growth was observed. 
Applications in pharmaceutical formulations & technology: 
 The resin or the mucilage (prior to drying) has been studied for its gel forming 
properties, using Diclofenac sodium as a model drug [17]. 
 It can be opted to replace synthetic or commercially available polymers to be 
used as a gelling agent or binding agent.  
 It also possesses inherent stomachic, sedative, laxative, aphrodisiac and anti-
inflammatory properties [25]. 
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II. Pectin [16] 
Synonyms : Cellulose, Kaopectate 
Source : Pectin is mainly obtained from citrus peel or apple 
pomades, both of which are by-products of juice 
manufacturing process Apple pomade contains 10–15% of 
pectin on a dry matter basis while Citrus peel contains of 
20–30%. 
Chemical structure : 
  
Molecular weight : 194.139 g/mol 
Constituents : Pectin is mainly composed of D-galacturonic acid units 
joined in chains by means of á-(1-4) glycosidic linkage. 
Functional Category : Stabilizing agent; gelling agent; thickening agent 
Description : Off-white colored amorphous, odorless, free-flowing, fine 
powder 
pH : 3.2-3.4 
Heat of combustion : 14.6 J 
Specific gravity : 1.6 at 25°C 
Solubility : soluble in ordinary water, partially soluble in cold water, 
insoluble in organic solvents and alcohol 
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Application in pharmaceutical formulation or technology 
Pectin is widely used in pharmaceutical formulations as gelling agent, 
thickener, water binder and stabilizer. It is compatible with most of the other 
pharmaceutical ingredients. It also has good stability and viscosity over a wide pH and 
temperature ranges. 
Safety 
Pectin is non-toxic and non-irritant at the levels employed as a 
pharmaceutical excipient 
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III. Sodium alginate [33]  
 
Synonyms : Algin, Sodium salt of Alginic acid, Kelcosol, Keltone, 
Manucol, Manugel, Pronova, Satialgine-H8  
 
Source : It is extracted from seaweed, algae, and bacteria 
Chemical structure : 
 
Molecular weight : 1828 g/mol 
Constituents : Alginate is composed of (1–4)-b-D-mannuronic acid (M) and 
(1–4)-a-L-glucuronic acid (G) units in the form of homo 
polymeric (MM- or GG-blocks) and hetero polymeric 
sequences (MG or GM-blocks) 
 
Functional category : Stabilizing agent; suspending agent; tablet and capsule 
disintegrant; tablet binder; viscosity-modifier. 
 
Description : white to pale yellowish brown colored powder 
pH : 7.2 
Melting point : 20°C 
Specific gravity : 1.26  
Viscosity : 20-400 mPa 
Solubility : slowly soluble in water, forming a viscous colloidal solution; 
practically insoluble in Ethanol, Diethyl ether, other organic 
solvents and acids. 
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Application in pharmaceutical formulation or technology 
Alginate and their derivatives are widely used by many pharmaceutical 
scientists for drug delivery and tissue engineering applications due to its many 
properties such as biocompatibility, biodegradability, water solubility, relatively low 
cost, gelling ability, stabilizing properties, and high viscosity in aqueous solutions. In 
topical formulations Sodium alginate is used as a thickening and suspending agent in 
variety of creams and gels and as a stabilizing agent for oil in water emulsion. 
 
Safety  
Low toxicity & non-immunogenicity are salient safety features of 
Sodium alginate, although excessive oral consumption may be harmful. 
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IV. Polyvinyl Alcohol [34] 
Synonyms : Poly(Ethenol), Ethenol, homopolymer, Polyviol, Vinol, Alvyl, 
Alcotex, Covol, Elvanol, Gelvatol, Lemol, Mowiol 
Source : It is synthesized by the polymerization of vinyl acetate to 
polyvinyl acetate (PVAc) which is then hydrolysed to get PVA. 
Chemical structure : 
 
Molecular weight : Ranges from 4000-200000 (the one which is used in this study 
is 160000), with a repeating monomer of weight 44.00 g/mol 
Functional category : film-forming agent; gelling agent; viscosity modifier; 
surfactant; bioadhesive. 
Description : colorless crystalline substance 
pH : 5.0-6.5 
Melting point : 200°C 
Specific gravity : 1.35 
Solubility : PVA is soluble in highly polar and hydrophilic solvents, such 
as water, Dimethyl Sulfoxide(DMSO), Ethylene Glycol (EG), 
and N-Methyl Pyrrolidone (NMP). The solubility of PVA in 
water depends on the degree of polymerization (DP), 
hydrolysis, and solution temperature. 
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Application in pharmaceutical formulation or technology 
PVA hydrogels have been used for various biomedical and 
pharmaceutical applications. It is bioadhesive in nature. It has high tensile strength and 
flexibility. PVA also shows a high degree of swelling in water (or biological fluids) and 
a rubbery and elastic nature and therefore closely simulates natural tissue and can be 
readily accepted into the body. PVA gels have been used for contact lenses, the lining 
for artificial hearts, and drug- delivery applications. PVA is mainly used in topical 
pharmaceutical and ophthalmic formulations. It is used as a stabilizer in emulsions. 
PVA is used as a viscosity increasing agent for viscous formulations such as ophthalmic 
products. It is used as a lubricant for contact lens solutions, in sustained release oral 
formulations and transdermal patches. 
 
Safety: 
 Advantages of PVA hydrogels are that they are non-toxic and non-
carcinogenic 
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OBJECTIVES OF THE STUDY 
 
 To establish the mucoadhesive property of a natural polymer obtained 
from fruits of B. flabellifer (Palmyra palm) plant. 
 
 To determine whether this novel natural polymer possess sustained 
release or immediate release pattern. 
 
 To formulate the drug Metadoxine in a novel dosage form, which is 
currently unavailable in the market. 
 
 To propose a new theory for calculation of dose, by incorporating 
thickness factor. 
 
 To determine whether the change in dosage form can enhance the 
bioavailability and thereby reduce the dosing frequency as well as dose 
dumping of the particular drug. 
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PLAN OF THE WORK 
 
 
Fig-5: Plan of the work 
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MATERIALS & EQUIPMENTS 
Table-1: List of materials and reagents used in the study 
Reagent Manufacturer 
Borassus flabellifer Resin Natural source 
Pectin Himedia Laboratories, Mumbai 
Sodium alginate S.D Fine Chemicals Ltd., Mumbai 
Polyvinyl alcohol (M.W:160000) Himedia Laboratories, Mumbai 
Sucrose S.D Fine Chemicals Ltd., Mumbai 
Vanillin Himedia Laboratories, Mumbai 
Metadoxine Apotex Research Pvt. Ltd. 
Polyethylene glycol - 400 Himedia Laboratories, Mumbai 
Dimethyl sulphoxide E. Merck Ltd., Mumbai 
Potassium dihydrogen phosphate S.D Fine Chemicals Ltd., Mumbai 
Sodium hydroxide S.D Fine Chemicals Ltd., Mumbai 
Potassium Bromide Himedia Laboratories, Mumbai 
Cellulose nitrate filter Sartorius 
 
Table-2: List of equipment and apparatus used in the study 
Equipments Model/Company 
UV/ Visible Spectrophotometer JASCO V-630 
Franz Diffusion Cell Fabricated 
FT-IR Spectrometer JASCO-4100 
Magnetic stirrer Remi Equipment 
Hot air oven INLAB Equipments Pvt. Ltd. 
Electronic digital micrometer Aerospace, China 
Electronic balance Shimadzu electronic balance 
Patch cutter  Fabricated 
pH tester Eutech instruments 
Disintegration tester Campbell electronics, Mumbai 
Double beam balance K. Roy Instruments, Hyderabad 
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PREFORMULATION STUDIES 
Preformulation studies are vital for any kind of formulation since they 
assure the success of the final product both physically and chemically. The important 
preformulation studies with respect to this work involves: 
1. Authentication of source of the Palmyra palm fruit resin 
2. Preparation of the Borassus flabellifer fruit resin 
3. Compatibility studies using FT-IR 
4. Preparation of calibration graph of Metadoxine using UV-visible 
spectrophotometry 
 
1. Authentication of source of the Palm fruit resin: 
Various parts of the Palmyra palm such as fruits (unripened and 
ripened), leaf with stalk and flower were submitted for identification and authentication 
of the botanical source to the Botanical Survey of India, Southern Regional Centre, 
Coimbatore. 
 
2. Preparation of B. flabellifer Fruit Resin (BFR) [25]: 
A ripened fruit of B. flabellifer was obtained from a local vendor. The 
black coloured peel of the fruit was removed and the three seeds along with the fibrous 
pulp was partitioned. Each portion of the fruit was boiled in hot water at 40°C. The 
sticky, yellow pulp was manually extracted from the fibers with the help of hot water. 
The process was continued till the fibers were free of yellow pulp and turn into pale 
colour.  
The seed and fibers were removed by means of filtration using a muslin 
cloth. The filtrate (fruit pulp) was concentrated by evaporating the liquid (at not more 
than 45°C), till the extract dried into a golden brown coloured sticky resin. The process 
of drying must be done carefully, since increase in temperature may char the product. 
The dried resin was stored in an air-tight container at room temperature. 
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3. Compatibility studies using FT-IR [35] 
 Compatibility studies are essential to study the interaction of the 
excipients with the drug, because it is an important criterion for any excipient, not to 
exhibit any kind of interaction with the drug. Therefore, in the present work, a study 
was carried out using infrared spectrophotometer to find out if there are any possible 
chemical interactions between drug and all the polymers used such as the new 
mucoadhesive polymer B. flabellifer fruit Resin (BFR), Pectin, Sodium alginate (SA) 
and PVA.   
4. Preparation of calibration graph of Metadoxine using UV-visible 
spectrophotometry [15] 
10mg of Metadoxine was dissolved in PBS pH-6.8 and the volume was 
made up to 100ml with the same, which gives a stock solution of 100µg/ml. From this 
stock solution aliquots of 0.4 – 4 ml were withdrawn using a pipette and transferred to 
a series of ten 10ml standard flasks. The volumes were made up with PBS pH-6.8. 
Thus, the concentration range of 4–40 µg/ml was obtained. The absorbances of the 
solutions were estimated at 324 nm using PBS pH-6.8 as reagent blank, with the help 
of UV-visible spectrophotometer. A triplicate of measurements was made to get mean 
absorbance values. A calibration graph of absorbance vs. concentration was plotted. 
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FORMULATION OF METADOXINE BUCCAL PATCHES 
1. Optimization of polymer ratios: 
 Almost 50 combinations of BFR with polymers such as Carbopol-940, 
HPMC. HEC, PVP, Gelatin, Pectin, Sodium alginate, PVA 6000, PVA 4000, PVA 
125000, PVA 160000 were tried to formulate buccal patches of formidable physical 
properties, by adding varying volume of plasticizer (PEG-400) and permeation 
enhancer (DMSO). Finally, 9 polymer ratios using Pectin, Sodium alginate and PVA-
160000 were found to be suitable. 
 
2. Dose calculation: 
The average thickness of patches made up by 10ml of formulation 
mixture without drug, found out after a number of trials (during optimization of 
polymer ratios) is 0.07 cm, using a digital screw gauge. Therefore, 
 Volume of a parent patch made up  
   by 10ml of formulation mixture = 3.1429 × 4.4 × 4.4 × 0.07 
 = 4.2593 cm3 
                 Volume of a single patch of radius 1cm = 3.1429 × 1 × 1 × 0.07 
 = 0.22 cm3 
     The number of possible patches (theoretically) = ସ.ଶହ9ଷ0.ଶଶ  
 = 19.3605 
                  Thus, the quantity of drug to be added = 19.3605 × 250 mg 
 = 4.8401 g  
 The parent patches of each formulation were cut into uniform pieces 
of buccal patches of fixed diameter, using a fabricated stainless steel punch with sharp 
edges.  
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3. Formulation of buccal patches by Solvent casting method: 
Weighed quantity of BFR was added to distilled water and dissolved 
using a magnetic stirrer set at 500 rpm to obtain a uniform solution. 12 formulations 
using Pectin (F1-F3), SA (F4-F6) and PVA (F7-F9) in varying proportions were added 
to each formulation.  
The rest of the ingredients such as sucrose (sweetening agent), Vanillin 
(flavoring agent), PEG-400 (plasticizer) and Dimethyl sulphoxide (permeation 
enhancer) were added in the order as given in the Table-1. Finally, the required quantity 
of Metadoxine was added to the polymer matrices. The formulation mixtures were 
poured to petri dishes of known diameter and allowed to air-dry at room temperature, 
by covering the dishes with a clean sieve or in a hot air oven at 30±5 °C, till the patches 
form a smooth non-sticky surface. 
Table-3: Composition of Metadoxine buccal patches 
Formulation 
Code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Ingredients (in mg) 
Metadoxine 4840  4840  4840 4840 4840 4840 4840 4840 4840 
BFR 300 400 500 400 400 400 300 400 500 
Pectin 500 400 300 - - - - - - 
SA - - - 200 300 400 - - - 
PVA - - - - - - 500 400 300 
Vanillin 60 60 60 60 60 60 60 60 60 
Sucrose 300  300  300  300  300  300  300 300 300 
 
in ml 
Water 10 10 10 10 10 10 10 10 10 
PEG 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
DMSO 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
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4. Application of backing membrane 
A suitable backing membrane prevents the buccal patch from releasing 
the drug through the non-adhering side. Hence, a backing membrane consisting of 4% 
PVA solution was sprayed over the dried patches only on one side. 
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EVALUATION OF THE BUCCAL PATCHES 
I. Thickness [8, 12, 36]: 
Thickness must be measure before application of backing membrane. A 
sample patch from each formulation code was taken and measured for thickness at 5 
different points using an electronic micrometer (digital screw gauge). Mean thickness 
and standard deviation values were calculated from the observed readings. 
 
II.  Weight variation test [8, 20, 21]: 
The same condition as above, measurement before application of 
backing membrane is followed. A random sample of 5 patches were taken from each 
formulation code and their individual weights were recorded. Mean weight and 
standard deviation values for each formulation was calculated. 
 
III. Folding endurance [20, 21, 23]: 
Folding endurance was determined by repeatedly folding a patch at the 
same point till the patch breaks into halves completely. The number of times the patch 
was folded till the point of break is considered as a patch’s folding endurance. 
 
IV. Swelling index [36]: 
Swelling index is directly related to the bioadhesive strength of a patch. 
One patch from each formulation code was taken in a pre-weighed basket made up of 
stainless steel mesh. The weights of each basket with patches were recorded. The 
baskets were placed in beakers; marked F1-F9; containing 4ml of PBS pH-6.8 each. 
After 10mins, the baskets were removed from the beakers, residual 
buffer solution were thoroughly strained and the weights were again noted. Swelling 
index for each formulation was calculated by the following equation. 
Swelling index = Wୣ୧୥୦୲ ୟ୤୲ୣ୰ ୱwୣ୪୪୧୬୥ −I୬୧୲୧ୟ୪ wୣ୧୥୦୲ I୬୧୲୧ୟ୪ wୣ୧୥୦୲  
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V. Surface pH[23]: 
A patch from each formulation code were placed in petri dishes and they 
were wetted with 1ml of demineralized water, and allowed to equilibrate for 30mins. 
The surface pH of each patch was measured by placing the tip of the pH meter electrode 
on the surface of the patch and holding for at least 10mins, till the pH value attains 
equilibrium. The procedure was repeated twice more to obtain average surface pH and 
standard deviation values. 
 
VI. Drug content assay [8, 23]: 
Drug content assay was carried out by dissolving the patch completely 
in 50ml of PBS pH-6.8, with the help of sonicator. Then, the volumes were made up to 
100ml with PBS pH-6.8. The solution is filtered. 1ml of this filtrate was further diluted 
to 100ml with PBS pH-6.8 and the absorbance was measured at Ȝmax of 324nm. The 
concentration of the solution was determined from the calibration graph, by 
interpolation. The drug content is determined by the following steps: 
Amount of drug present  
in a single patch (in mg)  =  େ୭୬ୡୣ୬୲୰ୟ୲୧୭୬ ୤୰୭୫ ୲୦ୣ ୥୰ୟ୮୦ × ୈ୧୪୳୲୧୭୬ ୤ୟୡ୲୭୰ଵ଴଴଴  
Assay/Percentage purity  =  A୫୭୳୬୲ ୭୤ ୢ୰୳୥ ୮୰ୣୱୣ୬୲ Lୟୠୣ୪୪ୣୢ ୡ୪ୟ୧୫  × 100 
where, the dilution factor  = 10000  
labelled claim  = 250mg 
Therefore, the steps can be simplified into one equation as follows: 
Drug content %  = Concentration from graph × 4 
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VII. Ex-vivo bioadhesion study [36]: 
a. Fabrication of the test assembly 
The working double beam balance formed the basis of the fabricated 
bioadhesion test apparatus. The left side pan was removed and replaced with a stainless 
steel wire (A) of gauge 1.2mm, hung with a Teflon coated glass tube (B) of diameter 
1cm, loaded with weights to equate the right side pan. The height of the total setup was 
adjusted to accommodate a Teflon block (E), of height 1.5cm and diameter 3.8cm with 
an upward protrusion of 1cm height 1.5cm diameter on one of its face, leaving a 
headspace of 0.5cm. The two sides were balanced so that the right side was 5g heavier 
than the left. 
b. Measurement of adhesion force 
The pig’s buccal mucosa (D) was excised, washed and was tightly tied 
over the protrusion of the Teflon block, with the mucosal side facing upwards. The 
setup was placed inside a glass beaker(F) with sufficient quantity of PBS pH-6.8, such 
that the buffer reaches the surface of the mucosal membrane and keeps it moist. This 
beaker was placed inside the left side of the balance. A patch (C) was stuck onto the 
Teflon coated tube (B) with a drop of water and the beam is raised by removing the 5g 
weight from the right side pan. This lowered the Teflon coated tube (B) along with the 
patch over the mucosa, with a weight of 5g. The balance was kept in this position for 
3mins and then weights were added gradually on the right pan till the patch gets 
separated from the mucosal surface completely. The excess weights of the pan i.e., the 
total weight subtracted by 5, gives the measure of force of detachment of the patch in 
grams. From this the bioadhesion strength can be calculated by 
Force of adhesion (N)  =  F୭୰ୡୣ ୭୤ ୢୣ୲ୟୡ୦୫ୣ୬୲ଵ଴଴଴  × 9.81 
The procedure was repeated for one patch from each formulation code. 
A fresh portion of tissue was used for each measurement. 
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Fig-6: Fabricated bioadhesion test assembly 
A – Stainless steel wire 
B – Teflon coated glass tube with weights 
C – Metadoxine buccal patch 
D – Pig buccal mucosa tissue 
E – Teflon block 
F – Glass beaker 
 
The results of all the above evaluation tests are given in Table-7. 
 
A 
B 
F 
C 
D 
E 
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VIII. In-vitro diffusion/permeation study [23]: 
In-vitro drug diffusion studies were performed by using Franz diffusion 
cell. It consists of a donor compartment and a receptor compartment. The receptor 
compartment is filled with 16ml of PBS pH-6.8 as the diffusion medium along with a 
magnetic bead. Over the filled receptor compartment, cellulose nitrate membrane of 
pore size 0.2ȝm was placed and allowed to moisten for 1min, to mimic buccal mucosa 
environment. Then a patch under study was placed over the membrane and closed 
tightly with the donor compartment. 
The whole assembly is fixed over a hot plate magnetic stirrer and the 
medium in the receptor compartment was subjected to stirring a 100rpm and the 
temperature of the diffusion cell is supplied constantly with flowing hot water at 37°±1° 
C to simulate the fluid and thermodynamics of the buccal environment. 
One ml samples were withdrawn 
from the sample port at predetermined 
time intervals with the help of a 1ml 
disposable syringe and the same volume 
was replaced with PBS pH-6.8. The 
samples were suitably diluted with the 
same medium and are analyzed for drug 
content at 324 nm, using PBS pH 6.8 as 
reagent blank. The unknown 
concentrations of the samples were 
obtained from the calibration graph of 
Metadoxine. The procedure is repeated 
for a sample patch from all formulations.  
 
 
The cumulative percentage release values for the respective time are 
tabulated (Table-8) and cumulative percentage release (%) vs time plots are drawn 
(Figures 20-22). 
 
Fig-7: Franz Diffusion cell 
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IX. In-vitro drug release kinetics [37] 
The order and mechanism of drug release kinetics of Metadoxine buccal 
patches were analyzed using the in-vitro diffusion study data, by plotting different 
kinetic models such as zero order, first order and Higuchi equations. The release pattern 
was determined using Korsmeyer-Peppas equations. 
 
a. Zero order kinetics model 
Cumulative percentage of drug diffused was plotted against time. 
 
Q=K0t 
 
where K0 is the zero order rate constant expressed in unit percentage of drug diffused 
(Q) /time (t) in hours. A graph of cumulative % drug diffused vs. time would yield a 
straight line with a slope K0 and intercept the origin of the axis. This kinetic model 
describe that the drug diffusion is concentration independent. 
 
b. First order kinetics model 
The pharmaceutical formulations following this kinetic model, release 
the drug in a way that is proportional to the amount of drug remaining in its interior, in 
such a way, that the amount of drug released diminish with time. First order kinetics 
graph is obtained by plotting log cumulative % drug diffused vs time. This kinetic 
model describe that the diffusion is concentration dependent. 
 
log Q = log Q0 – K1t / 2.303 
 
where Q is the cumulative % drug diffused at time ‘t’ 
Q0
 
is the cumulative % drug diffused at ‘0’ time 
K1
 
is the rate constant of first order kinetics 
 
c. Higuchi’s model 
Higuchi’s model is based on a plot of cumulative percentage of drug 
released vs. square root of time. 
Q = KH.t1/2 
 
where KH is the constant reflecting the design variables of the system and ‘t’ is the time 
in hours. This model describes the release of drug on the basis of Fickian diffusion as 
a square root of time dependent process from swellable matrix. 
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d. Korsmeyer-Peppas Equations 
Korsmeyer-Peppas equation is used to evaluate the release pattern, by 
using the equation 
Q = Kkptn 
 
where Q is the fractional solute release, t is the release time, Kkpis a 
kinetic constant characteristic of the drug/polymer system, and n is an exponent that 
characterizes the mechanism of release.   
The equation is subjected to modification by taking log on both sides, 
thereby the equation is  
log Q = log Kkp + n log t 
 
The exponent ‘n’ can be calculated through the slope of the linear graph 
of log cumulative percentage of drug released (log Q) vs. log time (log t).  The ‘n’ value 
is used to characterize the diffusion mechanism based on the data given in Table-4. 
 
Table-4: Diffusion exponent and diffusion mechanism 
Diffusion exponent Overall diffusion mechanism 
0.5 Quasi Fickian diffusion 
0.5 Fickian diffusion (Higuchi Matrix) 
0.5 n < 1.0 Non-Fickian diffusion 
1.0 Case 2 transport 
>1.0 Super case 2 transport 
Softwares such as DD Solver and Kinet DS are specifically programmed 
for calculating kinetic models. In this study, DD Solver was used to propagate 
respective graphs (Figures:23-31) of each model, using cumulative percentage release 
per time data. 
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RESULTS & DISCUSSIONS 
I. PREFORMULATION 
1. Authentication of source of the Palmyra palm fruit resin 
The source of the Palmyra palm resin was authenticated as the fruit pulp 
of Borassus flabellifer. L, belonging to family Arecaceae. 
 
2. Preparation of the Borassus flabellifer fruit resin 
 
Fig-8: B. flabellifer Fruit Resin 
 
3. Compatibility studies using FT-IR [30] 
The physical mixtures of Metadoxine and polymers were subjected to 
FT-IR analysis to identify any interaction between them.  
FT-IR spectra of Metadoxine, BFR, Pectin, Sodium alginate, PVA and 
mixtures of drug with each excipient are given in Figures 9-7.  
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Fig-9: Infrared spectrum of Metadoxine 
 
METADOXINE 
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Fig-10: Infrared spectrum of BFR 
BFR 
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Fig-11: Infrared spectrum of Pectin 
 
PECTIN 
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Fig-12: Infrared spectrum of Sodium alginate 
 
 
SODIUM ALGINATE 
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Fig-13: Infrared spectrum of PVA 
 
 
PVA 
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Fig-14: Infrared spectrum of BFR + Metadoxine 
 
 
BFR + METADOXINE 
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Fig-15: Infrared spectrum of Pectin+ Metadoxine 
 
 
PECTIN + METADOXINE 
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Fig-16: Infrared spectrum of Sodium alginate + Metadoxine 
 
 
SODIUM ALGINATE + METADOXINE 
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Fig-17: Infrared spectrum of PVA + Metadoxine 
  
PVA + METADOXINE 
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Table-5: Interpretation of IR spectra of drug, polymers & physical mixtures 
Functional 
group 
assignment 
Standard 
wave 
number 
(cm-1) 
Test wave 
number of 
Metadoxine 
(cm-1) 
Test wave number of polymers (cm-1) Test wave number of mixtures (cm-1) 
BFR Pectin 
Sodium 
alginate 
PVA 
BFR 
+ 
Drug 
Pectin 
+ 
Drug 
Sodium 
alginate 
+  
Drug 
PVA 
+ 
Drug 
O-H stretching 3200-3550 3462.56 3470.28 3531.99 3468.35 3467.38 3468.35 3463.53 3467.38 3468.35 
N-H stretching 
(aliphatic) 3310-3350 3327.57 - - - - 3330.46 3328.53 3327.57 3335.28 
C=O stretching 2500-3300 2870.52 2924.52 2912.95 2927.41 2869.56 2871.49 2881.13 2866.67 2867.63 
C-H bending 1650-2000 1900.5 1900.5 1900.5 1899.54 1902.43 1901.47 1898.58 1900.5 1901.47 
C=O stretching 1705-1725 1667.16 1675.84 1658.48 1656.55 1658.48 1671.02 1661.37 1697.05 1673.91 
N-H stretching 
(aromatic) 1266-1342 1281.47 - - - -  1280.5 1285.32 1279.54 
Wavenumbers for individual compounds and physical mixtures were compared in Table-5. There was no appearance or 
disappearance of any characteristic peak of the drug, which confirms the absence of chemical interaction between drug and the polymers. 
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4. Preparation of calibration graph of Metadoxine using UV-visible 
spectrophotometry 
The mean absorbance values for the standard concentrations of 
Metadoxine are given in the table-. It was found that the concentration of Metadoxine 
in the range 4-40µg/ml obeyed Beer-Lambert’s law. The correlation coefficient was 
found to be 0.997862. 
 
Table-6: Calibration graph of Metadoxine 
S. no Concentration (μg/ml) Absorbance 
1 4 0.1587 
2 8 0.1954 
3 12 0.3350 
4 16 0.4220 
5 20 0.5418 
6 24 0.6303 
7 28 0.7253 
8 32 0.8514 
9 36 0.9826 
10 40 1.0630 
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Fig-18: Calibration graph of Metadoxine 
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II. FORMULATION OF METADOXINE BUCCAL PATCHES 
 
1. Formulations F1-F3: combination of BFR + Pectin 
 
 
2. Formulations F4, F5 & F6: combination of BFR + Sodium alginate 
 
 
3. Formulations F7, F8 & F9: combination of BFR + PVA 
 
Fig-19: Photographs of Metadoxine buccal patches 
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III. EVALUATION OF METADOXINE BUCCAL PATCHES 
A. Evaluation of physico-chemical properties 
The results of physico-chemical evaluation tests such as thickness, weight variation, folding endurance swelling index, 
surface pH, drug content assay and bioadhesion strength are given as follows: 
Table-7: Physico-chemical evaluation test results of Metadoxine buccal patches F1-F9      
Formulation 
code 
Thickness 
(mm) 
Weight variation 
(mg) 
Folding 
endurance 
Swelling 
Index Surface pH 
Bioadhesion 
strength (N) 
Drug content 
assay (%) 
F1 0.7318 ± 0.02 425.8 ± 3.77 61 3.8125 6.83 ± 0.1 0.0183 97.6 
F2 0.7294 ± 0.03 383.6 ± 4.39 16 0.6279 6.56 ± 0.08 0.0086 94 
F3 0.6882 ± 0.02 399.6 ± 3.84 53 0.5152 6.51 ± 0.34 0.0398 90 
F4 0.6978 ± 0.01 343.4 ± 4.21 56 4.0909 7.34 ± 0.09 0.0256 95.2 
F5 0.7536 ± 0.01 350.2 ± 4.32 81 2.5857 6.84 ± 0.06 0.0360 96.8 
F6 0.7190 ± 0.09 361.2 ± 3.11 152 4.0667 5.99 ± 0.11 0.0392 85.6 
F7 0.7658 ± 0.02 399.8 ± 3.11 256 1.5455 7.17 ± 0.13 0.0187 99.6 
F8 0.7152 ± 0.06 390.6 ± 3.28 230 0.6154 7.06 ± 0.09 0.0144 100.8 
F9 0.6912 ± 0.03 386.8 ± 4.43 178 0.3571 6.89 ± 0.04 0.0271 96 
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Inference 
 The thickness of the patches ranges from 0.6882 ± 0.02 mm to 0.7658 ± 0.02 mm, 
which ascertains that the average thickness assumed(0.7mm) for dose calculation is 
valid. 
 
 The weighs of the patches of different formulation codes were in the range of 343.4 
± 4.21 mg to 425.8 ± 3.77 mg, whereas the intra-batch variation is relatively smaller 
with a maximum standard deviation of 4.43 mg (F9). 
 
 The patches F7-F9 exhibited remarkable folding endurance with values as high as 
256, whereby the lowest value of 16 was observed for F2. Increase in the additional 
polymer (Pectin/SA/PVA) increases the folding endurance, 
 
 Swelling index of all the formulations were relatively good, with highest swelling 
property exhibited by F4 (BFR : SA - 4:2) at 4.099. 
 
 The surface pH values of the formulations were in the range 5.99 ± 0.11 to 7.34 ± 
0.09, which indicates the patches have a similar pH to that of saliva (pH-6.8) and 
thus they will not irritate the buccal mucosa. A decrease in pH was observed with 
increase in BFR concentration, which is due to the inherent pH (5.5) of the polymer 
itself. 
 
 The force required to detach the patch from the animal’s tissue is directly 
proportional to the bioadhesion strength of the patches. In this aspect, the patch with 
highest bioadhesion strength (0.0398 N) was exhibited by F3 (BFR : Pectin – 5:3). 
This indicates that high concentration of BFR can help to retain the patch over the 
mucosa for a longer period, in spite of the mechanics of the facial tissues. 
 
 The test for drug content resulted in assay values as high as 100.8 % w/w and not 
less than 85.6% w/w, which proves that the method employed for formulation and 
dose calculation were appropriate and has good reproducibility. 
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B. Evaluation of percentage drug release 
Table-8: In-vitro permeation data of formulations F1, F2 & F3 
S.no Time (h) 
Cumulative percentage release % 
F1 F2 F3 
1 0 0 0 0 
2 0.5 1.64 3.49 3.57 
3 1.0 6.56 13.98 5.65 
4 1.5 12.96 15.63 7.143 
5 2.0 18.71 17.84 16.58 
6 2.5 19.69 37.84 31.43 
7 3.0 20.35 42.16 50.71 
8 3.5 38.73 47.78 58.73 
9 4.0 46.54 55.09 63.21 
10 4.5 59.58 69.32 70.22 
11 5.0 73.9 79.36 75.68 
12 5.5 80.6 87.23 86.98 
13 6.0 92.6 96.84 91.23 
 
 
Fig-20: In-vitro diffusion profile of formulations F1, F2 & F3 
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Table-9: In-vitro permeation data of formulations F4, F5 & F6 
S.no Time (h) 
Cumulative percentage release % 
F4 F5 F6 
1 0 0 0 0 
2 0.5 1.56 2.12 2.73 
3 1.0 4.24 5.57 3.07 
4 1.5 15.93 18.39 4.76 
5 2.0 28.75 26.98 5.24 
6 2.5 37.98 42.61 9.98 
7 3.0 51.69 54.00 12.4 
8 3.5 65.54 63.21 24.77 
9 4.0 74.65 70.02 38.68 
10 4.5 83.62 81.09 52.32 
11 5.0 88.82 85.64 72.26 
12 5.5 - 90.08 85.41 
13 6.0 - 93.21 - 
 
 
Fig-21: In-vitro diffusion profile of formulations F4, F5 & F6 
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Table-10: In-vitro permeation data of formulations F7, F8 & F9 
S.no Time (h) 
Cumulative percentage release % 
F7 F8 F9 
1 0 0 0 0 
2 0.5 1.72 4.15 6.86 
3 1.0 3.26 6.23 9.18 
4 1.5 10.32 11.59 11.52 
5 2.0 10.81 23.56 15.08 
6 2.5 12.17 39.58 31.83 
7 3.0 14.04 40.21 36.19 
8 3.5 33.14 47.65 40.86 
9 4.0 36.61 59.10 47.98 
10 4.5 40.29 76.09 58.65 
11 5.0 55.09 88.64 64.72 
12 5.5 63.74 95.12 73.69 
13 6.0 72.35 - 88.51 
 
 Fig-22: In-vitro diffusion profile of formulations F7, F8 & F9 
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Table-11: In-vitro permeation data of formulations F1- F9 
S.no Time (h) Cumulative percentage release % 
 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 0 0 0 0 0 0 0 0 0 0 
2 0.5 1.64 3.49 3.57 1.56 2.12 2.73 1.72 4.15 6.86 
3 1.0 6.56 13.98 5.65 4.24 5.57 3.07 3.26 6.23 9.18 
4 1.5 12.96 15.63 7.143 15.93 18.39 4.76 10.32 11.59 11.52 
5 2.0 18.71 17.84 16.58 28.75 26.98 5.24 10.81 23.56 15.08 
6 2.5 19.69 37.84 31.43 37.98 42.61 9.98 12.17 39.58 31.83 
7 3.0 20.35 42.16 50.71 51.69 54.00 12.4 14.04 40.21 36.19 
8 3.5 38.73 47.78 58.73 65.54 63.21 24.77 33.14 47.65 40.86 
9 4.0 46.54 55.09 63.21 74.65 70.02 38.68 36.61 59.10 47.98 
10 4.5 59.58 69.32 70.22 83.62 81.09 52.32 40.29 76.09 58.65 
11 5.0 73.9 79.36 75.68 88.82 85.64 72.26 55.09 88.64 64.72 
12 5.5 80.6 87.23 86.98 - 90.08 85.41 63.74 95.12 73.69 
13 6.0 92.6 96.84 91.23 - 93.21 - 72.35 - 88.51 
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C. Release kinetics 
The results of drug release kinetics study were tabulated on the basis of 
in-vitro diffusion study data. 
Table-12: Release kinetics data of F1 [BFR : Pectin – 3:5] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 1.64 0.214844 
3 1.0 1.0 0 6.56 0.816904 
4 1.5 1.2247 0.1761 12.96 1.112605 
5 2.0 1.4142 0.3010 18.71 1.272074 
6 2.5 1.5811 0.3979 19.69 1.294246 
7 3.0 1.7321 0.4771 20.35 1.308564 
8 3.5 1.8708 0.5441 38.73 1.588047 
9 4.0 2.0 0.6021 46.54 1.667826 
10 4.5 2.1213 0.6532 59.58 1.7751 
11 5.0 2.2361 0.6989 73.9 1.868644 
12 5.5 2.3452 0.7404 80.6 1.906335 
13 6.0 2.4495 0.7782 92.6 1.966611 
 
 
 
 
Chapter 10 Results & Discussions 
Department of Pharmaceutics 74 
 
 
 
 
   
R2 = 0.9064 R2 = 0.7947 
 
 
   
R2 = 0.6654 R2 = 0.9619 
Fig-23: Kinetic models of drug release from F1 
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Table-13: Release kinetics data of F2 [BFR : Pectin – 4:4] 
S.no 
Time-t 
(h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 3.49 0.542825 
3 1.0 1.0 0 13.98 1.145507 
4 1.5 1.2247 0.1761 15.63 1.193959 
5 2.0 1.4142 0.3010 17.84 1.251395 
6 2.5 1.5811 0.3979 37.84 1.577951 
7 3.0 1.7321 0.4771 42.16 1.624901 
8 3.5 1.8708 0.5441 47.78 1.679246 
9 4.0 2.0 0.6021 55.09 1.741073 
10 4.5 2.1213 0.6532 69.32 1.840859 
11 5.0 2.2361 0.6989 79.56 1.900695 
12 5.5 2.3452 0.7404 87.23 1.940666 
13 6.0 2.4495 0.7782 96.84 1.986055 
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 R2 = 0.9718 R2 = 0.8670 
 
 
   
 R2 = 0.7704 R2 = 0.9645 
Fig-24: Kinetic models of drug release from F2 
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Table-14: Release kinetics data of F3 [BFR : Pectin – 5:3] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 3.57 0.552668 
3 1.0 1.0 0 5.65 0.752048 
4 1.5 1.2247 0.1761 7.143 0.853881 
5 2.0 1.4142 0.3010 16.58 1.219585 
6 2.5 1.5811 0.3979 31.43 1.497344 
7 3.0 1.7321 0.4771 50.71 1.705094 
8 3.5 1.8708 0.5441 58.73 1.76886 
9 4.0 2.0 0.6021 63.21 1.800786 
10 4.5 2.1213 0.6532 70.22 1.846461 
11 5.0 2.2361 0.6989 75.68 1.878981 
12 5.5 2.3452 0.7404 86.98 1.939419 
13 6.0 2.4495 0.7782 91.23 1.960138 
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 R2 = 0. 9516  R2 = 0.8590 
 
 
   
 R2 = 0.7497   R2 = 0.9770 
Fig-25: Kinetic models of drug release from F3 
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Table-15: Release kinetics data of F4 [BFR : SA – 4:2] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 1.56 0.19312 
3 1.0 1.0 0 4.24 0.62737 
4 1.5 1.2247 0.1761 15.93 1.20222 
5 2.0 1.4142 0.3010 28.75 1.45864 
6 2.5 1.5811 0.3979 37.98 1.57955 
7 3.0 1.7321 0.4771 51.69 1.71341 
8 3.5 1.8708 0.5441 65.54 1.81651 
9 4.0 2.0 0.6021 74.65 1.87303 
10 4.5 2.1213 0.6532 83.62 1.92231 
11 5.0 2.2361 0.6989 88.82 1.94851 
12 5.5 2.3452 0.7404 - - 
13 6.0 2.4495 0.7782 - - 
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R2 = 0.9583 R2 = 0.8608 
 
 
  
R2 = 0.7456 R2 = 0.9932 
Fig-26: Kinetic models of drug release from F4 
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Table-16: Release kinetics data of F6 [BFR : SA – 4:3] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 2.12 0.32634 
3 1.0 1.0 0 5.57 0.74586 
4 1.5 1.2247 0.1761 18.39 1.26458 
5 2.0 1.4142 0.3010 26.98 1.43104 
6 2.5 1.5811 0.3979 42.61 1.62951 
7 3.0 1.7321 0.4771 54.00 1.73239 
8 3.5 1.8708 0.5441 63.21 1.80079 
9 4.0 2.0 0.6021 70.02 1.84522 
10 4.5 2.1213 0.6532 81.09 1.90897 
11 5.0 2.2361 0.6989 86.54 1.93722 
12 5.5 2.3452 0.7404 90.08 1.95463 
13 6.0 2.4495 0.7782 93.21 1.96946 
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 R2 = 0. 9732 R2 = 0.8952 
 
 
  
 R2 = 0.8099 R2 = 0.9885 
Fig-27: Kinetic models of drug release from F5 
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Table-17: Release kinetics data of F6 [BFR : SA – 4:3] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage 
of drug 
diffused-Q 
(%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 2.73 0.43616 
3 1.0 1.0 0 3.07 0.48714 
4 1.5 1.2247 0.1761 4.76 0.67761 
5 2.0 1.4142 0.3010 5.24 0.71933 
6 2.5 1.5811 0.3979 9.98 0.99913 
7 3.0 1.7321 0.4771 12.4 1.09342 
8 3.5 1.8708 0.5441 24.77 1.39393 
9 4.0 2.0 0.6021 38.68 1.58749 
10 4.5 2.1213 0.6532 52.32 1.71867 
11 5.0 2.2361 0.6989 72.26 1.8589 
12 5.5 2.3452 0.7404 85.41 1.93151 
13 6.0 2.4495 0.7782 - - 
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 R2 = 0. 7536 R2 = 0.6599 
 
 
  
 R2 = 0.4996 R2 = 0.9857 
Fig-28: Kinetic models of drug release from F6 
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Table-18: Release kinetics data of F7 [BFR : PVA – 3:5] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 1.72 0.23553 
3 1.0 1.0 0 3.26 0.51322 
4 1.5 1.2247 0.1761 10.32 1.01368 
5 2.0 1.4142 0.3010 10.81 1.03383 
6 2.5 1.5811 0.3979 12.17 1.08529 
7 3.0 1.7321 0.4771 14.04 1.14737 
8 3.5 1.8708 0.5441 33.14 1.52035 
9 4.0 2.0 0.6021 36.61 1.5636 
10 4.5 2.1213 0.6532 40.29 1.6052 
11 5.0 2.2361 0.6989 55.09 1.74107 
12 5.5 2.3452 0.7404 63.74 1.80441 
13 6.0 2.4495 0.7782 72.35 1.85944 
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 R2 = 0.8813 R2 = 0.8028 
 
 
  
 R2 = 0.6351 R2 = 0.9594 
Fig-29: Kinetic models of drug release from F7 
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Table-19: Release kinetics data of F8 [BFR : PVA – 4:4] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 4.15 0.61805 
3 1.0 1.0 0 6.23 0.79449 
4 1.5 1.2247 0.1761 11.59 1.06408 
5 2.0 1.4142 0.3010 23.56 1.37218 
6 2.5 1.5811 0.3979 39.58 1.59748 
7 3.0 1.7321 0.4771 40.21 1.60433 
8 3.5 1.8708 0.5441 47.65 1.67806 
9 4.0 2.0 0.6021 59.10 1.77159 
10 4.5 2.1213 0.6532 76.09 1.88133 
11 5.0 2.2361 0.6989 88.64 1.94763 
12 5.5 2.3452 0.7404 95.12 1.97827 
13 6.0 2.4495 0.7782 -  
 
 
 
 
 
 
 
 
 
Chapter 10 Results & Discussions 
Department of Pharmaceutics 88 
 
 
 
  
 R2 = 0.9485 R2 = 0.8365 
 
 
  
 R2 = 0.7262 R2 = 0.9705 
Fig-30: Kinetic models of drug release from F8 
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Table-20: Release kinetics data of F9 [BFR : PVA – 5:3] 
S.no Time-t (h) 
Square 
root of 
time - t1/2 
log t 
Cumulative 
percentage of drug 
diffused-Q (%) 
log Q 
1 0 0 0 0 0 
2 0.5 0.7071 -0.3010 6.86 0.83632 
3 1.0 1.0 0 9.18 0.96284 
4 1.5 1.2247 0.1761 11.52 1.06145 
5 2.0 1.4142 0.3010 15.08 1.1784 
6 2.5 1.5811 0.3979 31.83 1.50284 
7 3.0 1.7321 0.4771 36.19 1.55859 
8 3.5 1.8708 0.5441 40.86 1.6113 
9 4.0 2.0 0.6021 47.98 1.68106 
10 4.5 2.1213 0.6532 58.65 1.76827 
11 5.0 2.2361 0.6989 64.72 1.81104 
12 5.5 2.3452 0.7404 73.69 1.86741 
13 6.0 2.4495 0.7782 88.51 1.94699 
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 R2 = 0.9625 R2 = 0.8760 
 
 
   
 R2 = 0.7533 R2 = 0.9757 
Fig-31: Kinetic models of drug release from F9 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8
C
U
M
U
LA
T
IV
E
 P
E
R
C
E
N
T
A
G
E
 R
E
LE
A
S
E
 (
%
)
TIME (h)
ZERO ORDER MODEL
Observed
Predicted
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8
C
U
M
U
LA
T
IV
E
 P
E
R
C
E
N
T
A
G
E
 R
E
LE
A
S
E
 (
%
)
TIME (h)
FIRST ORDER MODEL
Observed
Predicted
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8
C
U
M
U
LA
T
IV
E
 P
E
R
C
E
N
T
A
G
E
 R
E
LE
A
S
E
 (
%
)
TIME (h)
HIGUCHI  MODEL
Observed
Predicted
0
10
20
30
40
50
60
70
0 1 2 3 4 5
C
U
M
U
LA
T
IV
E
 P
E
R
C
E
N
T
A
G
E
 R
E
LE
A
S
E
 (
%
)
TIME (h)
KORSMEYER -PEPPAS MODEL
Observed
Predicted
Chapter 10 Results & Discussions 
Department of Pharmaceutics 91 
 
Correlation of coefficient values various kinetic models with respect to 
the in-vitro diffusion study were tabulated to determine the best-fit model and the 
mechanism of diffusion. 
Table-21: Correlation of coefficient values various kinetic models 
Formulation 
Code 
Correlation coefficient value (R2) 
Zero order 
kinetic Model 
First order 
kinetic Model 
Higuchi’s 
Model 
Korsmeyer-
Peppas Model 
F1 0.9064 0.7947 0.6654 0.9619 
F2 0.9718 0.8670 0.7704 0.9645 
F3 0. 9516 0.8590 0.7497 0.9770 
F4 0.9583 0.8608 0.7456 0.9932 
F5 0. 9732 0.8952 0.8099 0.9885 
F6 0. 7536 0.6599 0.4996 0.9857 
F7 0.8813 0.8028 0.6351 0.9594 
F8 0.9485 0.8365 0.7262 0.9705 
F9 0.9625 0.8760 0.7533 0.9757 
Average 0.9381 0.8279 0.7061 0.9752 
Standard 
deviation 
0.04 0.07 0.09 0.01 
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Inference 
In-vitro permeation studies revealed that the formulation F7 (BFR : 
PVA- 3:5) exhibits a sustained release of more than 6 hrs and hence PVA is a suitable 
combination for BFR for a sustained release drug delivery. 
The release kinetic modelling shows that the formulated Metadoxine 
buccal patches undergo zero order kinetic release, since the correlation coefficient 
values corresponding to zero order model of all the formulations are comparatively 
higher and closer to 1.0 (averaging at 0.9381±0.04) than First order and Higuchi 
models. 
The Korsmeyer-Peppas modelling helped to determine the release 
mechanism of the buccal patch formulations as ‘non-Fickian mechanism’ (according 
to Table-4 &20), since the average ‘n’ exponent value is 0.9752 ± 0.01. 
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SUMMARY 
Natural polymers are trending as a reliable alternative for synthetic and 
semi synthetic polymers, in the development of a large number of novel drug delivery 
systems. One such new alternative to be used as a mucoadhesive polymer- B. flabellifer 
Fruit resin, especially for buccal drug delivery was introduced. 
The novel polymer, in combination with two other natural polymers 
(Pectin & Sodium alginate) and one synthetic polymer (PVA), was used to formulate a 
buccal drug delivery system containing Metadoxine. This drug was chosen due to its 
low half-life (maximum of 60 min) and attempt was made to reduce its dose by 
sustaining its release. Also alcoholism is a serious social and health issue affecting a 
significant amount of world population and hence a therapeutic alternative to cure 
alcoholism is a need of the hour. 
 Compatibility studies carried out with the help of FT-IR spectrometer 
indicated that there are no chemical interactions between the drug and the polymers 
used, including BFR. The calibration graph of Metadoxine was obtained by a validated 
UV spectrophotometric method at λmax of 324 nm. 
BFR was extracted from ripened palm fruit; stored and used for 
formulating 9 formulations in the ratios BFR : Pectin - 3:5, 4:4, 5:3 / BFR : SA – 4:2, 
4:3, 4:4 and BFR : PVA - 3:5, 4:4, 5:3 respectively (the numbers in the ratios indicate 
the polymer concentration in percentage). A backing membrane of 4% PVA was also 
coated over one side of all formulations. 
Physico-chemical properties such as thickness, weight variation, folding 
endurance, swelling index, surface pH, drug content and bioadhesion strength were 
evaluated appropriately and, the results were tabulated and compared. In-vitro diffusion 
study was also performed to examine the release pattern of the formulations, which was 
extended to determine the kinetics and mechanism of the release. 
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CONCLUSION 
Metadoxine buccal patches were formulated and evaluated successfully by 
solvent casting method; following standard operating procedures. The evaluation tests 
revealed that B. flabellifer is a suitable polymer for developing a sustained release 
buccal drug delivery system. Among the developed buccal patches, the formulation F7 
with a polymer combination of 3% w/v BFR and 5% w/v PVA seems to be an optimized 
formulation, since it exhibits better folding endurance, uniformity of drug content, and 
sustained release of drug. Therefore, Metadoxine which exhibits lower elimination half-
life can be incorporated in buccal drug delivery systems, in order decrease the dose 
frequency and thereby decreasing the possibility of dose dumping. 
 It also should be noted that, concentration of BFR is directly proportional to 
the bioadhesion strength and hence BFR justifies its selection as a novel mucoadhesive 
polymer of natural origin. 
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FUTURE PLAN & EXTENSION OF THE WORK  
This study proves that resin obtained from fruits of B. flabellifer has the 
potential to be used as formidable natural polymer. Hence it can also be used as  
 thickening agent or viscosity modifier 
 binding agent (when solubilized at low concentrations) 
 gelling agent 
 
If further attempts are made, it can be used alone as a film-forming 
polymer with the help of varying plasticizers [23]. 
In another aspect, this polymer can also be incorporated with fast 
disintegrating agents and developed into fast dissolving films. 
It is also evident that the plant possesses the same constituents elsewhere 
among its parts. One such variation in the source of this polymer can be unripe fruits of 
B. flabellifer [18]. But the difference is, it can be obtained as a coarse powder than a 
resin, if dried properly. 
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